Loading...
XAMS
LKFT
Market cap1.90bUSD
Jun 23, Last price  
25.36EUR
1D
1.60%
1Q
-4.59%
Jan 2017
-58.39%
IPO
257.18%
Name

Galapagos NV

Chart & Performance

D1W1MN
XAMS:LKFT chart
P/E
5.21
P/S
1.50
EPS
4.87
Div Yield, %
—
Shrs. gr., 5y
0.25%
Rev. gr., 5y
18.39%
Revenues
1.11b
+303.35%
35,152,00065,936,00076,978,00093,089,000122,410,00095,887,000136,268,000137,699,00069,368,00039,563,000129,517,000127,087,000288,836,000834,901,000478,053,000484,846,000241,249,000239,724,000275,649,0001,111,831,419
Net income
321m
+332.98%
-11,335,000-21,948,000-14,584,0003,010,0004,370,000-33,097,000-5,721,000-8,079,00033,211,000-118,410,00054,012,000-115,704,000-29,259,000149,845,000-305,436,000-125,422,000-217,991,000211,697,00074,082,000320,763,815
CFO
-197m
L-38.46%
-9,310,000371,000-8,209,0006,303,000-18,573,000-11,991,00064,104,000522,000-75,555,000-114,590,000239,403,000-147,030,000-142,466,0003,596,902,458-427,336,000-503,827,000-500,544,000-405,970,000-320,026,000-196,934,212

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
URL
https://www.glpg.com/
IPO date
May 06, 2005
Employees
1,233
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT